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Abstract
A major difficulty in treating cancer is the inability to differentiate between normal and tumor cells. The immune system
differentiates tumor from normal cells by T cell receptor (TCR) binding of tumor-associated peptides bound to Major
Histocompatibility Complex (pMHC) molecules. The peptides, derived from the tumor-specific proteins, are presented by
MHC proteins, which then serve as cancer markers. The TCR is a difficult protein to use as a recombinant protein because of
production issues and has poor affinity for pMHC; therefore, it is not a good choice for use as a tumor identifier outside of
the immune system. We constructed a synthetic antibody-fragment (Fab) library in the phage-display format and isolated
antibody-fragments that bind pMHC with high affinity and specificity. One Fab, fE75, recognizes our model cancer marker,
the Human Epidermal growth factor Receptor 2 (HER2/neu) peptide, E75, bound to the MHC called Human Leukocyte
Antigen-A2 (HLA-A2), with nanomolar affinity. The fE75 bound selectively to E75/HLA-A2 positive cancer cell lines in vitro.
The fE75 Fab conjugated with 64Cu selectively accumulated in E75/HLA-A2 positive tumors and not in E75/HLA-A2 negative
tumors in an HLA-A2 transgenic mouse as probed using positron emission tomography/computed tomography (PET/CT)
imaging. Considering that hundreds to thousands of different peptides bound to HLA-A2 are present on the surface of each
cell, the fact that fE75 arrives at the tumor at all shows extraordinary specificity. These antibody fragments have great
potential for diagnosis and targeted drug delivery in cancer.
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Introduction
One of the most important lessons learned about cancer in the
past 100 years is the understanding that each cancer is as unique
as the patient. Effective treatment of the patient is linked to
knowing which proteins, such as hormone receptors or HER2/
neu, are actively expressed in the tumor. Probes that allow us to
ascertain the molecular details of each patient’s tumors will greatly
enhance treatment. Biopsies can be used to determine molecular
details, but biopsy is invasive, not always possible and does not
allow for the fact that the tumor may change characteristics over
time or location [1]. It would be preferable to be able to perform
a noninvasive technique first followed by treatment [2]. Our long-
term goal is to develop agents that can specifically target tumor
cells for detection and delivery of toxins or chemotherapeutics.
Any noninvasive approach to determining molecular details of
the tumor must use a probe that binds to the tumor cells with high
affinity and high specificity. Monoclonal antibodies with affinity
for cell-surface receptors on tumors have had great success in the
clinic, but this approach appears to be limited because of the
expression of that same cell surface receptor on normal cells that
cause side effects during treatment. One of the best examples of
successful use of monoclonal antibodies to tumor-associated
antigens is Herceptin. Herceptin targets the human epidermal
growth factor receptor 2 (HER2/neu). HER2/neu is over-
expressed in 15–30% of solid tumors including breast, ovarian,
colorectal, esophageal, squamous head and neck and stomach [3].
Over-expression of HER2/neu correlates with poor prognosis for
therapy of breast cancer [4–8] and has been linked to increased
metastases [9]. Monoclonal antibodies directed towards HER2/
neu such as Herceptin have shown great efficacy in the clinic, but
patients do develop resistance over time [10] and some patients do
not respond at all [11]. Therefore, other approaches to target
HER2/neu over-expressing tumor cells would be of significant
value.
Our approach to targeting HER2/neu positive tumor cells is to
use the same mechanism that the immune system uses to target
and kill tumors, that is to target peptides derived from the HER2/
neu protein when bound and presented by the Major Histocom-
patibility Complex (MHC). The interaction of the T cell receptor
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(TCR) with peptide/MHC complex is the fundamental event that
triggers the adaptive immune response [12]. T cells identify tumor
cells by recognizing peptides derived from tumor-associated
molecules. The TCR would theoretically be an excellent probe
to use for tumors, except that the TCR is frequently not amenable
to manipulation and recombinant expression and its affinity for
particular pMHC is relatively poor (the dissociation constant in
the high mM range) [13–19]. Monoclonal antibodies would be
a much better approach, because they are robust molecules and
their production is well established. Antibodies that target specific
pMHC on the surface of tumor cells have been produced but for
some unknown reason, producing them conventionally is very
difficult. When available, these TCR-like antibody fragments
appear to bind similarly to TCR binding pMHC [20,21].
Antibodies (or antibody fragments) previously isolated from
phage-display libraries exhibited relatively low affinity for the
pMHC complexes [22–24].
In this study, we isolated a T-cell receptor like Fab that
specifically targets the HER2/neu peptide, E75 (KIFGSLAFL),
bound to the human MHC, Human Leukocyte Antigen, HLA-A2
from a synthetic antibody library using phage display. The Fab
binds with nanomolar binding affinity and high specificity for the
E75/HLA-A2 pMHC molecule. The Fab was then modified to
attach radioactive 64Cu and used for in vivo PET/CT imaging
experiments on tumor-bearing mice that express HLA-A2
transgenically. The Fab showed increased retention in the
HER2/neu pMHC positive tumors compared to HER2/neu
pMHC negative tumors. These TCR-like antibodies can be used
to study antigens presented on diseased and antigen-presenting




This study was completed in strict accordance with the
Association for Assessment and Accreditation of Laboratory
Animal Care at the University of North Carolina (UNC) Animal
Facility and the mice were handled according to the UNC Office
of Animal Care and Use. All experimentation was in accordance
with the protocol (08–235.0) approved by the UNC Institutional
Animal Care and Use Committee.
Cells and Culture Conditions
MDA-MB-231, MCF7, and LNCAP tumor cells, CHO cells,
T2 lymphoblast cells were purchased from ATCC. SKOV3 and
SKOV3 cells transfected with HLA-A2 were a generous gift from
Dr. Jonathan Serody (Department of Microbiology, UNC –
Chapel Hill, NC) [25]. Unless otherwise mentioned all media
supplies were purchased from Mediatec, Inc. (Manassas, VA).
Each of the cell lines were grown in RMPI 1640 supplemented
with 10% heat-inactivated FBS (Atlanta Biologicals, Inc.; Law-
renceville, GA), 10 mM sodium pyruvate, and penicillin/strepto-
myocin in humidified CO2 (5%) incubator at 37uC. SKOV3
transfected HLA-A2 cells and CHO transfected HLA-A2 cells
were grown in the same conditions as above with the addition of
2.5 mg/ml G418.
Antibodies and synthetic peptides
Anti-c-erb B-2 Ab-2 (9G6.10) was purchased from NeoMarkers
(Fremont, Ca). Alexa Fluor 647 labeled Goat anti-mouse IgG1, PE
labeled mouse IgG2b, and Alexa Fluor 647 labeled Streptavidin
were purchased from Invitrogen, Inc. PE labeled mouse anti-
Human HLA-A2 clone BB7.2 was purchased from BD Bios-
ciences. The peptides: E75 (from HER2/neu; KIFGSLAFL,
residues 369–377); ML (from calreticulin; MLLSVPLLL, residues
1–9); YM (from human papillomavirus 16 (HPV-16) E7
oncoprotein; YMLDLQPETT, residues 11–20); RL (from
HER2/neu; RLLQETELV, residues 689–697); HY (from
HER2/neu; HLYQGCQVV, residues 48–56); KT (from gp100
glycoprotein; KTWGQYWQV, residues 154–162); IL (from HIV-
1 RT ILKEPVHGV; residues 476–484); and HA (from influenza
hemagglutinin; IYSTVASSL, residues 518–526) were synthesized
by the UNC Peptide Synthesis Facility (Chapel Hill, NC).
Generation of peptide bound HLA-A2 complexes
The human MHC, HLA-A2.1, human beta-2-microglobulin
(b2M), mouse beta-2-microglobulin, and murine H-2 K
d were
produced as inclusion bodies in E. coli BL21 (DE3) (Invitrogen,
Inc.). Protein was folded in vitro as described previously [26].
Briefly, peptide, b2M, and HLA-A2 heavy chain in a 10:1:1 molar
ratio were injected into a folding buffer consisting of 100 mM Tris
pH 8.0, 400 mM arginine, 2 mM EDTA, 5 mM glutathione
(reduced), 0.5 mM glutathione (oxidized), and protease inhibitors
PMSF, pepstatin and leupeptin. The total final protein concen-
tration was never greater than 50 mg/ml. After incubation for 24–
36 hours at 10uC the folded pMHC was concentrated in an
Amicon ultrafiltration cell (Millipore, Billerica, MA) and purified
using gel filtration chromatography (Phenomenex, Inc.; Torrance,
CA). The purified pMHC molecules were concentrated to greater
than 3 mg/ml and stored at 280uC until use. Typical yield for
each 1 L refold is about 5 mg of pMHC, which is approximately
a 14% yield. The pMHC was site specifically biotinylated with the
biotin ligase BirA (Avidity, LLC; Aurora, Colorado) according to
the manufacturer’s instructions. A non-denaturing SDS PAGE gel
shift assay (no reducing agent, no heat treatment) was used to
confirm that the pMHCs were biotinylated.
Construction of Fab library
We first constructed a template plasmid for constructing
libraries, pFab007. This plasmid contains a modified version of
the Fab-4D5 gene [27] fused to gene III of the M13 phage
(corresponding to the carboxyl-terminal 208 residues of pIII). This
fusion protein contains the cysteine residue of the heavy chain
hinge region so as to enable bivalent display of the Fab [28]. Most
residues in the CDR-L3, H1, and H2 loops were replaced with
serine. A TAA stop codon and a unique BamHI site were
introduced to CDR-H3. The gene was assembled from a series of
synthetic oligonucleotides using PCR. The synthesized gene and
the phoA promotor segment were cloned into a phage-display
vector, pAS38 [29] in such a way that the heavy chain of the Fab is
fused to the carboxyl-terminal 208 residue segment of M13 phage
pIII. The expression of both the light chain and the heavy chain-
p3 fusion were placed under the control of the phoA promotor.
The library was constructed as follows. Oligonucleotides that
encode biased amino acid mixture (indicated as ‘‘X’’s in Figure 1B)
for CDR-L3 and H3 were synthesized using a custom-made trimer
phosphoramidite mixture (Glen Research, Sterling, VA) on an
Expedite synthesizer (ABI) following instructions from Glen
Research. After deprotection, the oligonucleotides were purified
using acrylamide gel electrophoresis. Oligonucleotides for CDR-
H1 and H2 that did not require the use of trimer phosphor-
amidetes were purchased from Integrated DNA Technologies.
These oligonucleotides were used to introduce mutations of CDR-
L3, CDR-H1, CDR-H2 and CDR-H3 using the Kunkel
mutagenesis method [30]. After the initial transformation of the
SS320 cells [30], the DNA for the library was purified and digested
with BamHI and then used to transform the SS320 cells and
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produce phage particles, as described [27]. In this manner clones
harboring non-mutated CDR-H3 were eliminated. This Fab
library, ‘‘Library E,’’ contained approximately 1010 independent
clones.
Selection of phage-displayed antibody fragments
The library sorting was performed as previously described [27]
with minor modifications. From the second round on, enriched
phages were first incubated with streptavidin-coated magnetic
beads, and phages that bound to the beads were removed. The
‘‘precleared’’ phages were then incubated with biotinylated
pMHCs in solution and then captured with the streptavidin-
coated magnetic beads. The pMHC concentrations used were
100, 50, 10 and 10 nM for the first, second, third and fourth
rounds, respectively. Phages captured on the beads were eluted in
100 ml of 0.1 M Gly-HCl (pH 2.1) buffer and immediately
neutralized with 35 ml of 1M Tris-Cl buffer (pH 8). Recovered
clones were analyzed using phage ELISA and DNA sequencing as
described previously [27].
Expression and purification of soluble recombinant Fabs
The phage-display vectors for the isolated clones were converted
into Fab expression vectors by inserting a gene segment encoding
an 8x histidine tag and a termination codon at the 39 end of the
heavy chain gene. The carboxyl terminus of the light chain
encoded a substrate tag for the biotin ligase BirA (AviTag, Avidity,
LLC.). Fab proteins were expressed in the 55244 E. coli strain
(ATCC) and purified using protein A affinity chromatography
followed by cation exchange chromatography as described pre-
viously [27]. Approximately 2–5 mg of purified Fab were routinely
obtained from 1 L bacterial culture. SDS-PAGE analysis showed
that Fabs were in .90% purity.
Surface Plasmon Resonance Experiments
Approximately three hundred response units (RUs) of each
antibody fragment were bound to respective flow channels in
a Biacore Ni-NTA sensor chip (GE Healthcare) using the 8x
histidine tag on the antibody fragments. Soluble class I MHC
(analyte) at concentrations ranging from 200 nM to 1 nM in two
fold dilutions was injected onto the surface at a flow rate of 20 ml/
min in a 60-s pulse. The NTA surface was regenerated using
0.2 M EDTA to remove all bound protein and then recharged
with 0.04 M NiSO4. The procedure was repeated until at least
three curves were obtained for each concentration of analyte.
Curves obtained at each concentration were double referenced by
first, subtracting the signal from the reference surface that
contained no Fab from the signal for the reaction surface followed
by subtraction of the average signal obtained from a set of buffer
injections [31]. Data were processed using Scrubber (BioLogic
Software, Campbell, Australia). The suitability of the fit was
measured based on the appearance of residuals and x2 values. For
each Fab-pMHC binding curve, the predicted curves visually
overlaid well with the experimental curves. The residuals also were
small and random and x2 was below 1.
Production of Fab Tetramers
Purified Fabs were biotinylated using a site-specific biotin-ligase
BirA (Avidity, LLC; Aurora, Colorado) according to the
manufacturer’s instructions. As described above for the biotinyla-
tion of pMHC, successful biotinylation of the Fabs was confirmed
by gel shift analysis. Biotinylated Fabs were incubated with
streptavidin-alexa 647 (Invitrogen, Inc.) at a 4 to 1 molar ratio for
ten minutes at room temperature to make the Fab tetramers.
Flow cytometric analysis of peptide-loaded HLA-A2 on
cell surface
T2 cells are deficient in the TAP1 and TAP2 proteins that are
responsible for transporting antigenic peptides from the cytoplasm
to the endoplasmic reticulum, but are able to be loaded with
exogenous peptides for loading of HLA-A2 molecules on their cell
surface. T2 cells (16106/ml) were incubated in RPMI medium
and incubated with one of the peptides E75, ML, IL, YM, RL,
HL, KT, or IL (50 mM) overnight. After the incubation, the cells
were washed to remove the excess peptide and incubated with
either BB7.2 Ab (0.5 mg/ml) to detect the level of HLA-A2
molecules present on the surface or the complex of biotinylated
fE75 or fML1 with streptavidin-alexa 647 (Invitrogen, Inc.) for
30 min. at 4uC. Incubating the T2 cells with peptides leads to an
observable increase in BB7.2 staining compared with untreated
cells. In all experiments, the IgG2b isotype control was included
for determining nonspecific binding. Flow cytometry data were
analyzed using Summit software (Beckman Coulter, Inc.).
Tumor Cell Staining
All adherent tumor cell lines were detached from the tissue
culture flask using 16 trypsin/EDTA (Sigma-Aldrich, LLC). Cells
were washed and then incubated with anti-HER2/neu antibody
(Anti-c-erb B-2 Ab-2, 9G6.10) for 30 min. at 4uC followed by
incubation with Alexa Fluor 647 labeled Goat anti-mouse IgG1
and PE labeled HLA-A2 clone BB7.2 to analyze the phenotype of
each tumor cell line. Separately, each tumor cell line was prepared
as before, but stained with Fab-Alexa Fluor 647-streptavidin
tetramer for 30 min. at 4uC. After the final staining incubation,
cells were washed and analyzed by flow cytometry (Cyan,
Beckman Coulter, Inc.). Pearson’s correlation coefficient and
multiple linear regression analysis were completed for the mean
and median fluorescence intensity observed for each cell line’s
HLA-A2, Her2/neu, and Fab staining. No difference was
observed whether mean or median fluorescence was used for the
analysis.
DOTA Conjugation and 64Cu Radiolabeling
All solvents were prepared from 18MV water and eluted from
a column of chelex 100 (Serological Research Institute) to remove
metals from all buffers. Free metals were removed from purified
Fabs by dialysis twice with 1L of 0.2 M NaHCO3 at pH 8.2. Fabs
were conjugated to S-2-(4-Isothiocyanatobenzyl-)1,4,7,10-tetraa-
zacyclo-dodecane-tetraacetic acid (DOTA-NCS) purchased from
Macrocyclics (Dalax, TX) by using the isothiocyanate linkage
method as described previously [32]. The molar ratio of the
DOTA conjugate to Fab used was 5:1. The reaction proceeded at
pH 8.2 in 0.2 M NaHCO3 over 18 hours at room temperature.
Unconjugated DOTA was removed from the reaction by a PD-10
desalting column (GE Healthcare). The average number of
chelates per Fab was determined as described previously [33].
The positron emitting isotope 64Cu (copper chloride in 0.1 mol/L
HCl; radionuclide purity, .99%) was provided by Mallinckrodt
Institute of Radiology (Washington University School of Medicine,
St. Louis, WA). The DOTA-conjugated Fab (20 mM) was
incubated with approximately 1.5 mCi of 64CuCl2 in 1.0 mM
citric acid (pH 5.5). The solution was incubated for 1 hr at 40uC.
The reaction was monitored by TLC (silica) and developed with
0.1 M ammonium acetate (25%)/0.001 M citric acid (25%)/
methanol (50%). Free 64Cu was complexed as 64Cu citrate with an
Rf .0.5 and 64Cu DOTA-Fab had an Rf ,0.5. The radiochem-
ical yield was determined to be .97.0%.
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Cell Binding Assay of Radiolabeled fE75 Fab
The SKOV3 cells transfected with HLA-A2 were harvested as
previously described for tumor cell staining. The cells were
incubated with the purified 64Cu DOTA-Fab at increasing
concentrations for 30 min. at 4uC. As a demonstration of
specificity, the SKOV3 transfected HLA-A2 cell line was
incubated with 64Cu DOTA-Fab at increasing concentrations
and 300 nM soluble E75/HLA-A2 pMHC. Following the in-
cubation, the cells were washed twice and then the bound
radiolabeled fE75 counts per minute (cpm) was measured with
a 2470 WIZARD2 automatic gamma counter (PerkinElmer Inc.).
Micro Positron Emission Tomography/Computed
Tomography (microPET-CT) Imaging in Tumor-bearing
mice
The preliminary experiments used NOD.SCID (SCID) mice
with single tumors injected subcutaneously into the flank of the
mouse. SCID and HLA-A2 transgenic NOD.SCID mice were
a gift from Dr. Jeffrey Frelinger (Department of Immunobiology,
University of Arizona) [34]. All SCID mice were injected
subcutaneously on either the right or left flank with either negative
control tumors 16106 SKOV3 (4 mice) or positive tumors
SKOV3 transfected HLA-A2 cells (3 mice). Following these
experiments, we used HLA-A2 transgenic SCID mice and because
of limitations in the number of available mice, injected both
tumors on opposite flanks of each mouse. The HLA-A2 transgenic
SCID mice were injected with 16106 MDA-MB-231 cells and
SKOV3 cells on opposite flanks (3 mice). Mice were monitored
every other day by palpation and the size of tumor growth was
measured. Once the tumor growth could be observed by
palpation, mice were injected with the Fab and imaged using
a microPET-CT (eXplore Vista PET-CT, GE HealthCare, Inc.).
Mice were injected with approximately 20 mg of 64Cu-DOTA-Fab
(specific activity: 50–60 mCi/mg) in PBS via the tail vein. For all
scans, mice were anesthetized using 2% isoflurane, positioned in
a prone position along the long axis of the microPET scanner and
imaged. Dynamic PET acquisitions were taken over the first hour
for selected mice. Static acquisitions were taken for 10 min. at one-
hour post injection for all mice. All mice were additionally imaged
by micro computed tomography (microCT) prior to the microPET
scan in the same bed position for anatomical reference. Following
the imaging, tumors were excised, cryopreserved with liquid
nitrogen, and cryosectioned for radiographic analysis. PET images
were reconstructed using an ordered subsets-expectation maximi-
zation (OSEM) algorithm with scatter, random, and attenuation
corrections, and the PET pixel size was
0.387560.387560.775 mm [35]. Standardized uptake values
(SUVs) were calculated pixel-wise by normalizing for injected
dose and animal mass. The PET images were coregistered with the
microCT images using the scanner software for identification of
anatomical structures. Reconstructed microPET and microCT
images were viewed and regions of interest (ROIs) drawn and
SUVs quantified using AMIDE [36]. Tumor ROIs were drawn
manually to avoid adjacent organs and tumor metastases because
the metastases typically had very poorly defined borders. Average
SUV was measured for each specified ROI. The student’s t test
was used to compare the SUVs from single tumor bearing SCID
mice. The paired student’s t test was used to compare the SUVs
from the tumors of the double tumor-bearing, HLA-A2-transgenic
SCID mice.
Results
Generation of synthetic antibody-fragments specific to
pMHC complexes
Our goal is to develop tools to target specific tumor cells in vivo
for diagnostic testing and treatment. We hypothesized that
peptides bound to MHC would be good targets for such tools.
The HER2/neu peptide E75 (KIFGSLAFL) was selected for
analysis based on its clinical relevance to HER2/neu over-
expression [37–39] and the success of E75 peptide vaccines and
targeting using E75 in peptide-pulsed dendritic cell immunization
therapies [40,41]. It has been notoriously difficult to create
monoclonal antibodies (mAb) to specific peptide/MHC com-
plexes, presumably because of the sequence conservation between
MHC molecules injected and present in the immunized mouse
[42].
As an alternative to conventional mAb production, we sought to
isolate antibody-fragments (Fabs) specific for peptide-bound MHC
molecules using phage-display technology. We utilized a ‘‘synthet-
ic’’ antibody library built on a highly stable 4D5 Fab scaffold
(Figure 1A) [43] in which the amino acid diversity in the
Complementarity Determining Regions (CDR) was designed using
simple but highly tailored amino acid mixtures [27]. Because such
synthetic antibody libraries are not subjected to clonal selection
against self-antigens, unlike common recombinant antibodies
derived from natural immune systems, we felt that synthetic
antibody libraries, coupled with phage-display selection, offered
a particularly effective approach to generating antibodies to
pMHCs. Based on our previous work [27], we constructed a new
antibody library in which four of the six CDRs were diversified, as
described in Figure 1B. This library is similar to ‘‘Library D’’ of
Fellouse et al. [27], but its amino acid diversity in CDR-L3 was
expanded and also the composition of the expanded amino acid
diversity, designated as X in Figure 1, was modified based on the
analysis of antibody clones isolated from Library D [27].
We used the HER2/neu derived peptide, E75 (KIFGSLAFL),
or calreticulin derived peptide, ML (MLSVPLLL), bound to the
human MHC molecule HLA-A2 as the targets for sorting the
synthetic antibody library. After four rounds of selection, an
ELISA was used to test for specificity of the amplified phage
Figure 1C. We identified three distinct classes of antibodies: (i)
selective to E75/HLA-A2, (ii) selective to ML/HLA-A2, and (iii)
cross-reactive to the two pMHCs. Two clones, fE75 and fML,
selective to E75/HLA-A2 and ML/HLA-A2 respectively, were
chosen for further study based on the phage ELISA, which
identified each phage clone to have high affinity and specificity for
their respective pMHC. As expected, the two clones have distinct
CDR sequences (Figure 1D).
To assess the binding affinity, kinetics and specificity of the two
Fabs, they were produced as soluble proteins, with a His-tag at the
C-terminus of the heavy chain and a biotinylation tag at the C-
terminus of the light chain and characterized using Surface
Plasmon Resonance. The results shown in Figure 2 demonstrate
that the model appropriately describes the binding responses of
each Fab for its cognate pMHC molecule, with curve fitting
residuals at or below 1 RU. The KD value for fE75 binding E75/
HLA-A2 was determined to be 59 +/2 4 nM based on three
separate experiments (Figure 2A). The KD for fML binding ML/
HLA-A2 was 79 +/2 4 nM based on three separate experiments
(Figure 2D). No binding was observed for fE75 and fML binding
the non-cognate pMHC (Figure 2B, 2C), or to other non-cognate
pMHC molecules that differed in peptide alone or unrelated
peptide bound to unrelated MHC (data not shown).
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Fabs bind to cell surface pMHC
In order to test whether these Fabs can be used to find specific
pMHC on the cell surface, Fab-displaying streptavidin tetramers
were made and used to bind to peptide pulsed T2 cells. The T2
cell line is deficient in pMHC cell surface expression due to the
absence of the transporter associated with antigen processing
(TAP1 and TAP2). The MHC HLA-A2 on the surface of T2 cells
is more ‘‘peptide-receptive’’ than on normal cells and therefore;
specific peptides may be loaded onto HLA-A2 by incubating these
cells with exogenous peptides [44]. T2 cells were incubated with
ML, E75 or control peptides. The biotinylated Fabs were
respectively conjugated to fluorescently-labeled streptavidin to
form ‘‘Fab tetramers’’. The fE75 tetramer bound to T2 cells
incubated with E75 (Figure 3A), but not to untreated cells.
Similarly, the fML tetramer bound to T2 cells incubated with ML
(Figure 3B), but not to untreated cells. Additionally, neither Fab
bound to T2 cells incubated with any of the control peptides
(Figure 3C). Therefore, in agreement with the SPR experiments,
these Fabs bound specifically to their cognate pMHC expressed on
the cell surface.
The Fabs detect endogenously processed and presented
pMHC complexes
Addition of exogenous peptide to T2 cells generates a much
higher density of the particular peptide/MHC molecule on the cell
surface compared with endogenous levels found on normal TAP
expressing cell types [45,46]. Thus, we evaluated the ability of
fE75 and fML to recognize physiological levels of peptide
presented by the HLA-A2 molecule using flow cytometric analysis
of several human tumor cell lines: MDA-MB-231 breast tumor
cells (HLA-A2pos and HER2/neupos); SKOV3 HLA-A2 trans-
fected ovarian tumor cells (HLA-A2pos and HER2/neupos); MCF7
breast tumor cells (HLA-A2pos and HER2/neupos); LNCaP
prostate tumor cells (HLA-A2pos and HER2/neupos); and negative
control SKOV3 ovarian tumor cells (HLA-A2neg and HER2/
neupos). All the cell lines express HER2/neu at varying levels.
Thus, as anticipated, the HLA-A2 positive human cell lines
showed variable fE75 binding compared to the negative control
tumor cell line SKOV3 (HLA-A2neg) as shown in Figure 3D. All of
the HLA-A2 positive cell lines had similar binding of the fML Fab
(Figure 3E), but comparable to fE75, neither Fab bound to the
HLA-A2 negative control cell line SKOV3 (Figure 3F). In
addition, a further control was added with a CHO cell line
transfected with HLA-A2. This cell line was HLA-A2 positive but
HER2/neu negative. No binding of either fE75 or fML1 was
observed for this cell line (data not shown).
Next, we sought to understand the cause for the differences in
fE75 binding to the tumor cell lines in order to improve our ability
to use the TCR-like Fabs as diagnostic and treatment tools. The
cell surface level of peptide/HLA-A2 complexes is dependent on
Figure 1. Phage-Display isolation of Fabs Specific for pMHC Molecules. Fabs specific for either E75/HLA-A2 or ML/HLA-A2 molecules were
selected by phage-display technology. Each Fab construct was built from the highly stable 4D5 Fab scaffold containing both a heavy and light chain
each with a single variable and constant domain (modeled from PDB ID: 1FVD) (A). The diversity of the Complementary Determining Regions (CDR)
for the heavy chain; H1, H2, and H3, and the light chain; L3, was restricted in favor of tyrosine, serine, and other small amino acids. The Ca atoms of
the synthetically modified H1, H2, H3, and L3 regions are shown as spheres (B). After three rounds of selection, an ELISA was used to test the
specificity of the amplified clones (C). Three clones with three different specificities were identified. The Fab clones fE75 and fML bound E75/HLA-A2
and ML/HLA-A2 respectively with no detectable binding to the opposite pMHC molecule. The Fab clone fE2 showed binding to both E75/HLA-A2 and
ML-HLA-A2. Following each Fab clone’s specificity determination, the amino acid sequence of each clone was determined (D).
doi:10.1371/journal.pone.0043746.g001
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multiple parameters including: protein antigen availability, peptide
generation by the proteasome, antigen processing, and MHC
expression [47]. The data allow us to determine which protein
plays a more important role in the level of any particular pMHC
complex at the cell surface: MHC (HLA-A2) or antigen (HER2/
neu). We measured HER2/neu and HLA-A2 expression by flow
cytometry. There were significant differences in both HLA-A2
expression and HER2/neu levels between the cell lines (Figure 4A–
F). The MDA-MB-231 cell line had the highest level of HLA-A2
expression, but also the lowest HER2/neu levels. Both MCF7 and
LNCaP cell lines had intermediate levels of HER2/neu, but lower
expression of HLA-A2. The SKOV3 HLA-A2 cell line had the
highest level of HER2/neu and the second highest MFI of HLA-
A2.
Simple two-dimensional linear regression analysis models
showed weak correlation of fE75 MFI with HLA-A2 (r2 = 0.40)
and weak, but stronger correlation with HER2/neu expression
(r2 = 0.62) (Figure 4 G-H). Both of the regression analyses were
dominated by the contribution made by MDA-MB-231. If that
cell line were removed from the analysis, no correlation exists for
fE75 MFI and HLA-A2 (r2 = 0.09) nor HER2/neu (r2 = 0.00).
Since that is not meaningful biologically and we know that fE75
binding did vary for each cell line, we know that either there was
another unknown important factor or that both HLA-A2 and
HER2/neu influenced fE75 binding. The coordinated involve-
ment of both HLA-A2 and HER2/neu on fE75 levels was
modeled using multi-parameter linear regression analysis [48].
This model gave an excellent fit for the correlation of fE75 binding
using both HLA-A2 and HER2/neu expression levels (r2 = 0.97).
Removing the MDA-MB-231 cell line from this analysis showed
that there was still a significant correlation (r2 = 0.89), suggesting
that even though MDA-MB-231 appears to dominate the
regression, the correlation between fE75 binding and both HLA-
A2 and HER2/neu is valid even without the MDA-MB-231 cell
line. These data show that both MHC expression levels and the
antigen expression affect pMHC expression on tumor cell lines.
Both MHC and source of the peptide antigen must be considered
in order to accurately predict pMHC expression levels.
The TCR-like Fab recognizes E75/HLA-A2 positive tumors
in a xenotransplanted-tumor mouse model
To address whether the TCR-like Fabs can be used in vivo, we
used positron emission tomography-computed tomography (PET-
CT), which provides excellent sensitivity to radiolabels, allowing
quantification of the uptake of the imaging agent at the tumor
[49]. The Fab, fE75, was made into a PET imaging agent by
attaching a chelator, S-2-(4-Isothiocyanatobenzyl)-1,4,7,10-tetra-
azacyclo-dodecane-tetraacetic acid (DOTA-NCS). The DOTA
chelator provides flexibility as it can chelate both 64Cu for PET
and 111In for single-photon emission computed tomography
(SPECT). We routinely obtained an average of 0.7 moles of
DOTA per mole of fE75. The yield of 64Cu- fE75-DOTA
conjugate was obtained in greater than 95% purity as determined
Figure 2. TCR-like Fabs Bind Cognate pMHC with Nanomolar Affinity. SPR binding response curves of fE75 binding E75/HLA-A2 (A) and ML/
HLA-A2 (B) and fML binding E75/HLA-A2 (C) and ML/HLA-A2 (D) are shown. Each Fab was immobilized onto individual flow channels in an NTA-Ni
chip. Kinetic data for each Fab binding each pMHC molecule were globally fit to a bimolecular reaction. Green and blue lines designate the start and
end respectively of each pMHC injection. Binding curves and curve fits are drawn in black and orange respectively. Each binding curve represents
a different concentration of pMHC beginning at 200 nM and decreasing to 1.5 nM in 2 fold dilutions. No binding was observed for either Fab binding
non-cognate pMHC molecules up to 400 nM.
doi:10.1371/journal.pone.0043746.g002
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by thin layer chromatography. To confirm that addition of this
chelator and the radioactive metal did not alter the binding affinity
of fE75 for E75/HLA-A2, in vitro cell binding studies were
performed. The ovarian tumor cell line SKOV3 transfected with
HLA-A2 was incubated with a range of concentrations of
radiolabeled Fab. A Scatchard analysis was used to calculate
a binding affinity of 111 nM (95% CI: 63–159), which was in good
agreement with the SPR data (59 +/2 4 nM). The 64Cu- DOTA-
fE75- conjugate maintained its specificity for E75/HLA-A2, as
soluble recombinant E75/HLA-A2 complexes were able to block
binding of the radio-labeled fE75 to SKOV3/HLA-A2 cells
(Figure S1).
The first test of uptake of the labeled fE75 used SCID mice.
These mice do not express either human HER2/neu or HLA-A2.
The question asked is whether once the Fab is injected into the tail
vein, will it be able to accumulate in the tumor. The 64Cu-
DOTA-fE75 conjugate was injected via the tail vein of severe
combined immunodeficiency (SCID) mice bearing either xeno-
transplanted SKOV3 or SKOV3 HLA-A2 tumors. MicroPET
(color) and microCT (black and white) images of the mice were
collected and overlayed (Figure 5A and5B). The xenografted
human tumors on either the left or right flanks were clearly
identifiable in all microPET/CT images. The relatively small size
of the Fab (,55 kDa) was below the renal clearance threshold of
approximately 64 kDa meaning that it should be rapidly
eliminated by renal clearance [50–55]. Literature indicated that
the large signal from the liver might be attributed to Cu/Zn
superoxide dismutase (SOD1), chelation of the 64Cu [56,57].
Tumors have been shown to trap injected materials non-
specifically [58], but, there was very little uptake of 64Cu-
DOTA-fE75 in the HLA-A2 negative SKOV3 control tumor
(Figure 5A, C; labeled ct) suggesting that this is not a significant
problem in our model. In contrast, there was easily observable
uptake of the fE75 imaging agent in the HLA-A2 positive tumor
(Figure 5B, D; labeled pt). Even after one hour, increased up-take
at the HLA-A2 positive tumor sites was observed, but not at the
negative control tumor. Accumulation of 64Cu-DOTA-fE75 was
observed at the edges of the tumor that suggested at first that the
Fab did not penetrate the tumor well. However, visual inspection
of the sectioned tumor showed necrosis in the center of the tumor
and radiography of the tumors (Figure S2) showed that the Fab
was bound appropriately on the outside where live tissue remains.
PET/CT images of additional human tumor bearing SCID mice
were shown in Figure S3. These data showed that the Fab does
accumulate at the site of the correct tumor.
Dynamic scans over the course of sixty minutes (Figure 5E and
5F), show that there is an initial rapid accumulation of 64Cu-
DOTA-fE75 followed by a steady-state in all the tissues (liver,
kidney, humoral muscle, and control tumor) except for the HLA-
A2 positive tumor. The HLA-A2 positive tumors showed initial
rapid accumulation followed by a steady rise in the 64Cu- fE75-
DOTA signal suggesting that specific binding occurs. The ratio of
Figure 3. Fabs bind specifically to endogenously processed and presented levels of pMHCmolecules. Flow cytometric analysis revealed
that the Fab tetramer, composed of biotinylated fE75 (A) or fML (B) and streptavidin-Alexa-647, bound to T2 cells incubated with the cognate
peptide, but not to control peptides or untreated T2 cells in three separate experiments. In C, a graph of the MFI for several other control peptides
against the cognate peptide for each Fab was shown. The staining of HER2/neu positive tumor cell lines by the fE75 and fML tetramers was shown in
D and E respectively. The graph of the MFI for one representative experiment from four total was shown in F.
doi:10.1371/journal.pone.0043746.g003
T Cell Receptor-Like Recognition of Tumor In Vivo
PLOS ONE | www.plosone.org 7 August 2012 | Volume 7 | Issue 8 | e43746
the slope of the Standard Uptake Values (SUVs) from 300 to 3600
sec. for the HLA-A2 positive tumors compared to the HLA-A2
negative control tumors was 6.6. This was expected if 64Cu-
DOTA-fE75 were to accumulate due to binding to its cognate
pMHC, E75/HLA-A2, at the HLA-A2 positive tumors. Further-
more, an unpaired t test analysis of the SUVs of the 64Cu-DOTA-
fE75 signal sixty minutes post injection gave a statistically
significant difference between the HLA-A2 positive tumors and
the HLA-A2 negative tumors (p,0.004, n = 4). Together these
experiments demonstrate that the fE75 Fab can accumulate in
tumors that present E75/HLA-A2 on their cell surface in vivo.
While the experiments above show that 64Cu-DOTA-fE75 can
target a pMHC in vivo, they do not mimic an important
consideration for human use. In humans, most cells in the body
Figure 4. HLA-A2 and HER2/neu expression is high variable on each tumor cell line. The surface expression of HLA-A2 and HER2/neu for
each human tumor cell line was measured by flow cytometry. The representative plots of HLA-A2 versus HER2/neu for each tumor cell line were
shown in A-E. In F, a graph of the MFI of one representative experiment from four total was shown. G and H were plots of the MFI of fE75 versus the
MFI of HLA-A2 or MFI of HER2/neu respectively. Simple two-dimensional linear regression analysis models do not model the system well. The black
lines showed weak correlation of fE75 MFI with HLA-A2 (r2 = 0.40) or HER2/neu expression (r2 = 0.62).
doi:10.1371/journal.pone.0043746.g004
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Figure 5. TCR-like Fab bind specifically to human tumor cells in SCID mice. Mice were injected intravenously with 64Cu-DOTA-fE75, which
binds to tumors expressing both HLA-A2 and HER2/neu in vivo. Coronal views of small-animal PET images with coregistered CT images of SCID mice
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express HLA-A2 bound numerous different peptides found in each
cell type [59,60]. If the 64Cu-DOTA-fE75 imaging agent has
a small degree of non-specific binding to HLA-A2 with other
peptides, we would not see accumulation at the tumor because the
Fab would be greatly diluted by the nonspecific binding before
arriving at the tumor. Thus, we used an HLA-A2 transgenic
mouse crossed to the SCID background, which allows for the
tumors to grow and for all of the mouse cells to express HLA-A2.
The HLA-A2 transgenic SCID mice were xenografted with the
SKOV3 (control tumor, ct) and MDA-MB-231 (positive tumor, pt)
(Figure 6A, B and Figure S3C). Dynamic scans were obtained over
sixty minutes following tail-vein injection of 64Cu-DOTA-fE75
(Figure 6C). The dynamic curves from the HLA-A2 transgenic
SCID mice were similar to what was seen in the SCID mice that
did not express HLA-A2 (Figure 5E–F). The ratio of the calculated
slopes of the SUVs from 300–3600s for the HLA-A2 positive
tumor compared to the HLA-A2 negative control tumor was 3.8,
again indicating positive accumulation of 64Cu-DOTA-fE75 at the
HLA-A2 positive tumor. Furthermore, comparison of the SUVs
sixty minutes post injection showed that the human tumors
positive for HLA-A2 and HER2/neu had statistically significant
uptake and retention of 64Cu-DOTA-fE75 compared to the
negative control tumor SKOV3 (paired t test, p,0.03, n = 4). This
is a significant achievement in specificity because the 64Cu- fE75-
DOTA was exposed to millions of HLA-A2 molecules with various
peptides and still accumulated at the HLA-A2 positive tumors.
Discussion
Our long-term goal is to construct a generalized approach to
specifically target tumors in vivo for diagnostic and therapeutic use.
We have used imaging as our first goal because we rationalize that
if we can image specifically, we can target therapeutics specifically.
We began with the observation that the immune system is fully
competent to target tumors in vivo [61–70]. A major portion of this
response is composed of cytotoxic T cells. T cells are able to
recognize peptides derived from proteins in the cells, bound to
MHC molecules (pMHC) using their clonotypic T cell receptor
[71,72]. Unfortunately for the patient, the tumor infiltrating T
cells do not always kill the tumors. As a substitute for tumor
specific recombinant T cell receptors, monoclonal antibodies that
recognize specific pMHC complexes have been generated
[24,45,46,73–80], but usually have low affinities compared to
those isolated from bacteriophage libraries [78,81–83]. Rational
design of high affinity antibodies directed towards pMHC has
yielded affinities in the nanomolar range [84], but that approach is
laborious and must be done for each antibody individually.
The Fabs isolated from our synthetic antibody-fragment library
have binding affinities in the mid-nM range, consistent with
a previous work demonstrating the ability of these synthetic
libraries to generate high-affinity antibodies without the need for
affinity maturation [27]. The level of affinity of our Fabs is
approximately 1000 times better than that for TCRs binding
pMHC, which is typically in the mM range [85]. This is also
roughly a 100-fold improvement over TCR-like monoclonal
antibodies produced from classical hybridoma technology [86].
These Fab have affinities similar to other peptide/HLA-A2-
specific antibodies isolated from bacteriophage libraries [87,88].
Previous studies have suggested that the higher affinity of TCR-
like Fab compared to T cell receptor is due to faster on-rates
instead of slower off-rates [89]. Our data are partially consistent
with this concept as our Fabs bind cognate pMHC with faster rates
of association, but our Fabs also show significantly slower rates of
dissociation. Therefore, increased affinity of TCR-like Fabs is not
solely due to increased on-rates as has been suggested.
Using these Fabs, we have shown that predicting pMHC levels
on the cell surface is dependent highly on both MHC and HER2/
neu antigen expression. Different tumor cell lines showed varying
levels of fE75 binding/staining because they have highly different
levels of HLA-A2 and HER2/neu. In agreement with previous
data [90], we observed no direct correlation between levels of
E75/HLA-A2 detected by fE75 and HER2/neu detected by mAb
suggesting that HER2/neu levels are not directly correlated with
E75/HLA-A2 levels on the cell’s surface. However, multiple
components are involved in the levels of any particular pMHC
and often these components may affect one another. Logically, it
seems likely both HER2/neu and HLA-A2 levels would affect
E75/HLA-A2 levels on the cell surface. Multi-parameter linear
regression analysis yielded a strong correlation between fE75
binding and the both HLA-A2 and HER2/neu expression. We
conclude that both variables, the source protein and MHC levels,
are both highly important.
The fE75 Fab was demonstrated to bind selectively to HLA-A2
positive tumors in vivo in SCID mice. Thus, fE75, a TCR-like Fab,
can be used in vivo and potentially used as a drug delivery vehicle.
This is consistent with other reports that demonstrate that tumors
xenografted in SCID mice were reduced or even eliminated as via
complement fixation or induction of apoptosis [24,91]. Moreover,
a TCR-like Fab fused to a truncated form of Pseudomonas exotoxin,
PE38KDEL showed in vivo dose dependent xenografted tumor
killing in SCID mice [87,92]. Immunotherapy and drug deliver by
TCR-like Fabs is possible only if the specificity of the Fab is
exceptional and does not bind to similar pMHC presented on
healthy cell surfaces.
However, our tests went one important step farther than those
performed previously. We showed that these TCR-like Fabs can
function similarly to human T cells; they can be highly selective in
vivo even in the context of human HLA-A2 expressed in HLA-A2.
Even with the thousands of peptide/HLA-A2 complexes available
on healthy cells of the HLA-A2 transgenic SCID mouse, the Fab
still accumulated at the transplanted tumors. This is especially
interesting considering that the sequence of the peptide E75 from
HER2/neu is identical to that found in mouse epidermal growth
factor receptor 2 [93] and that the HLA-A2 expression in the
HLA-A2 transgenic mouse model is expressed at comparable
levels to H-2Db in thymus, bone marrow, and spleen [94]. The
dynamic scans showed initial rapid accumulation of 64Cu- DOTA-
fE75 followed by a steady-state in all the tissues (liver, kidney,
humoral muscle, and control tumor) except for the HLA-A2
positive tumor similar to the SCID mouse experiments. It is not
clear why we did not see accumulation of the Fab in sites other
than the tumor and those predicted by the injection of this sized
protein. Although the mouse antigen presenting machinery can
process and present peptides recognized by human HLA-A2-
restricted T cells [93], it is possible that there are differences that
bearing human tumor (SKOV3 or SKOV3 HLA-A2) xenografts (A and B) in flanks at 1 h post-injection. Intensities of PET slices were scaled to the same
maximum. Cropped views of only the tumors designated by the white boxes for the mice presented in A and B were shown in C and D respectively.
The standardized uptake values (SUV) for 64Cu-DOTA-fE75 in the tumors and selected organs over time were shown below each respective mouse (E
and F). B = bladder, h = humeral muscle, k = kidneys, l = liver, ct = control HLA-A2 negative tumor; SKOV3 cell line, pt = HLA-A2 positive tumor;
SKOV3 HLA-A2.
doi:10.1371/journal.pone.0043746.g005
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preclude presentation of the E75 peptide or that the expression
level is so much lower in normal cells that there is a very small
dilution of the signal compared to the tumor.
Theoretically, the best in vivo images of the 64Cu-DOTA-Fab
accumulation would occur after removal of the unincorporated
label, but the half-life of fE75 binding to E75/HLA-A2 measured
by SPR is on the order of minutes and due to the high
vascularization of the tumors, the Fab is removed readily. We
conclude that all of these Fab sized probes of roughly 55 kDa
could be highly specific and bind very tightly, but they do not have
a long enough half-life to be useful on their own unless they are
endocytosed by the cell. The signal could be greatly increased by
multimerization of the Fab [95,96]. However, this problem does
not diminish the significance of the observation that the Fab
targeting was successful even in the context of transgenic
expression of HLA-A2 in all the cells of the mouse.
Antibodies specific for pMHC are useful tools for understanding
antigen presentation in vivo and allowing targeted therapy for
cancer. Not only can they be used to directly visualize T-cell
epitopes [45,90,97], they can aid in method development for
peptide-based immunotherapy, where visualization of a particular
pMHC before and after treatment would be beneficial. This can
include analysis of intracellular generation, trafficking, cell surface
expression, and stability of pMHC complexes on antigen
presenting cells (APC). Antibody fragments with pMHC specificity
can improve on the successes of adoptive T-cell therapy. Even
though up to 50% of patients treated with ex vivo expanded tumor-
infiltrating lymphocytes show clinical responses [70,98], it is not
possible to produce significant quantities of tumor infiltrating T
cells from all cancer patients due to the inability to either isolate or
expand them in vitro. There is promise in the field of genetically
modified T-lymphocytes, where TCR-like antibodies are trans-
ferred to T lymphocytes via retroviral infection for their expression
on the T cell surface [99]. T cells expressing tumor-specific
receptors, chimeric antigen receptors and modified TCRs
specifically killed tumor cells and had antitumor effects in vivo
[100–103].
In summary, we have demonstrated that pMHC specific Fabs
can be quickly and efficiently isolated from our skewed bacterio-
phage library. These particular Fabs provide much greater
stability and higher affinity than would T cell receptors making
them particularly good imaging agents. One of the Fabs, fE75,
shown to have high affinity and high specificity, was derivitized as
an in vivo imaging agent and selectively localized to HLA-A2
positive tumors in SCID HLA-A2 transgenic mice. It is anticipated
that phage display-derived TCR-like antibody fragments have
a wide range of applications in research, diagnostic, and
therapeutic applications.
Supporting Information
Figure S1 Saturation (N) binding curves of 64Cu-DOTA-
fE75 and SKOV3 HLA-A2 (E75/HLA-A2 pMHC positive)
cells. Each data point represents the mean 6 standard error of
the mean of triplicate measurements. The KD of
64Cu-DOTA-
fE75 was determined to be 111 nM (95% CIs: 63–159). 64Cu-
DOTA-fE75 binding (O) to SKOV3 HLA-A2 cells blocked by 300
nM soluble E75/HLA-A2 pMHC.
(TIF)
Figure 6. TCR-like Fab bind specifically to human tumor cells in
HLA-A2 transgenic SCID mice. Similarly as describe for the SCID
mice experiments (Figure 5), HLA-A2 transgenic SCID mice were
injected intravenously with 64Cu-DOTA-fE75. Coronal views of the small-
animal PET image with coregistered CT images of a scid HLA-A2
transgenic mouse bearing human tumor (MDA-MB-231 and SKOV3)
xenographs (A) in flanks at 1 h post-injection. Intensities of PET slices
were scaled to the same maximum. Cropped views of only the tumors
designated by the white boxes were shown in B respectively. The
standardized uptake values (SUV) for 64Cu-DOTA-fE75 in the tumors and
selected organs over time were shown in C. B = bladder, h = humeral
muscle, k = kidneys, l = liver, ct = control HLA-A2 negative tumor;
SKOV3 cell line, pt = HLA-A2 positive tumor; MDA-MB-231 cell line.
doi:10.1371/journal.pone.0043746.g006
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Figure S2 Radiography images of excised human tu-
mors from 64Cu-DOTA-fE75 injected SCID and HLA-A2
trangenic SCID mice. HLA-A2 positive and HLA-A2 negative
tumors from SCID mice were shown in A and B. HLA-A2 positive
and HLA-A2 negative tumors from HLA-A2 transgenic SCID
mice were shown in C–F.
(TIF)
Figure S3 Additional PET/CT images of SCID and HLA-
A2 transgenic SCID mice. Mice were injected intravenously
with 64Cu-DOTA-fE75, which binds to tumors expressing both
HLA-A2 and HER2/neu in vivo. Coronal views of small-animal
PET images with coregistered CT images of SCID mice bearing
human tumor (SKOV3 or SKOV3 HLA-A2) xenografts (A and B)
or HLA-A2 transgenic SCID mouse bearing two tumors (SKOV3
and MDA-MB-231) xenografts (C) in flanks at 1 h post-injection
were shown. Intensities of PET slices were scaled to the same
maximum. Cropped views of only the tumors designated by the
white boxes for the mice presented in A, B, and C were shown in
D, E and F respectively. B = bladder, h = humeral muscle, k =
kidneys, l = liver, ct = control HLA-A2 negative tumor; SKOV3
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